Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo

Clinical Cancer Research

Volumn 17, Issue 6, 2011, Pages 1373-1381

  Kudo, Kanae ^a,b   Arao, Tokuzo ^a   Tanaka, Kaoru ^a   Nagai, Tomoyuki ^a   Furuta, Kazuyuki ^a   Sakai, Kazuko ^a   Kaneda, Hiroyasu ^a   Matsumoto, Kazuko ^a   Tamura, Daisuke ^a   Aomatsu, Keiichi ^a   De Velasco, Marco A ^a   Fujita, Yoshihiko ^a   Saijo, Nagahiro ^a   Kudo, Masatoshi ^b   Nishio, Kazuto ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Gastroenterology ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CD45 ANTIGEN; FLUOROURACIL; INTEDANIB; PHOSPHOTYROSINE; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; LEUKOCYTES; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79952725305     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2755     Document Type: Article

References (28)

1. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009;59:111-37.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
4. Brown AP, Citrin DE, Camphausen KA. Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev 2008;27:415-34.
5. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, et al. Compressing drug development timelines in oncology using phase "0" trials. Nat Rev Cancer 2007;7:131-9.
6. Sessa C, Guibal A, Del Conte G, R€uegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008;5:378-91.
7. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-27. (Pubitemid 46622051)
8. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-25. (Pubitemid 32176299)
9. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer and leukemia group B 9480. Clin Cancer Res 2001;7:1932-6. (Pubitemid 32994827)
10. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Yamashita H, et al. Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. Breast Cancer 2003;10:120-8.
11. Werther K, Christensen IJ, Nielsen HJ; Danish prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002;86:417-23. (Pubitemid 34185127)
12. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045-54. (Pubitemid 47218051)
13. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8.
14. Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R,, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010;9:2825-33.
15. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82.
16. Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwäble J, et al. Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Mol Cancer Ther 2006;5:3105-12. (Pubitemid 46092052)
17. Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 2007;13:3051-7. (Pubitemid 46849582)
18. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small inframe deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 2004;64:9101-4. (Pubitemid 39665524)
19. Arao T, Yanagihara K, Takigahira M, Takeda M, Koizumi F, Shiratori Y, et al. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer 2006;118:483-9. (Pubitemid 41782165)
20. Márquez MG, Galeano A, Olmos S, Roux ME. Flow cytometric analysis of intestinal intraepithelial lymphocytes in a model of immunodeficiency in Wistar rats. Cytometry 2000;41:115-22.
21. Ganzer R, Blana A, Gaumann A, Stolzenburg JU, Rabenalt R, Bach T, et al. Topographical anatomy of periprostatic and capsular nerves: quantification and computerized planimetry. Eur Urol 2008;54:353-60.
22. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006;6:835-45. (Pubitemid 44629895)
23. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERKpathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. (Pubitemid 39331023)
24. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
25. Lau GM, Lau GM, Yu GL, Gelman IH, Gutowski A, Hangauer D, et al. Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci 2009;54:1465-74.
26. Yang WJ, Chang CJ, Yeh SH, Lin WH, Wang SH, Tsai TF, et al. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3beta kinase pathways. Hepatology 2009;49:1515-24.
27. Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol 2009;65:55-66.
28. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008;14:6146-53.